TY - JOUR
T1 - Novel Chimeric Gene Therapy Vectors Based on Adeno-Associated Virus and Four Different Mammalian Bocaviruses
AU - Fakhiri, Julia
AU - Schneider, Marc A.
AU - Puschhof, Jens
AU - Stanifer, Megan
AU - Schildgen, Verena
AU - Holderbach, Stefan
AU - Voss, Yannik
AU - El Andari, Jihad
AU - Schildgen, Oliver
AU - Boulant, Steeve
AU - Meister, Michael
AU - Clevers, Hans
AU - Yan, Ziying
AU - Qiu, Jianming
AU - Grimm, Dirk
N1 - Funding Information:
J.F. and D.G. are grateful for funding from the Cystic Fibrosis Foundation (CFF, grant GRIMM15XX0), the German Research Foundation (DFG, Cluster of Excellence CellNetworks, EXC81), as well as from the Heidelberg Biosciences International Graduate School HBIGS at Heidelberg University. D.G. acknowledges additional funding by the German Center for Infection Research (DZIF, BMBF; TTU-HIV 04.803). M.A.S. and M.M. acknowledge funding by the German Center for Lung Research (DZL, BMBF; 82DZL00402). J.E.A. and D.G. are grateful for support through the MYOCURE project. MYOCURE has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement 667751. S.B. and D.G. appreciate support from the Collaborative Research Center SFB1129 (German Research Foundation, DFG; TP14 to S.B. and TP2 to D.G.). S.B. was supported by a research grant from the Chica and Heinz Schaller Foundation. V.S. and O.S. are grateful to the Beatrix-Lichtken-Stiftung Cologne for funding. Z.Y. and J.Q. appreciate funding through grant AI139572 from the National Institute of Allergy and Infectious Diseases, NIH, USA. This work was further supported by the gravitation program NOCI: 024.003.001 from the Netherlands Organisation for Scientific Research (NWO). Finally, we thank Janina Haar for sharing various primary cells including human hepatocytes and cells shown in Figure 4A; Manuela Nickl for providing T cells; as well as Andrea Imle, Kathleen Börner, and David Bejarano (all Department of Infectious Diseases/Virology, Heidelberg University Hospital, Heidelberg, Germany) for preparing and providing PBMCs and macrophages.
Funding Information:
J.F. and D.G. are grateful for funding from the Cystic Fibrosis Foundation (CFF, grant GRIMM15XX0 ), the German Research Foundation (DFG, Cluster of Excellence CellNetworks, EXC81 ), as well as from the Heidelberg Biosciences International Graduate School HBIGS at Heidelberg University . D.G. acknowledges additional funding by the German Center for Infection Research (DZIF, BMBF; TTU-HIV 04.803 ). M.A.S. and M.M. acknowledge funding by the German Center for Lung Research (DZL, BMBF; 82DZL00402 ). J.E.A. and D.G. are grateful for support through the MYOCURE project. MYOCURE has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement 667751 . S.B. and D.G. appreciate support from the Collaborative Research Center SFB1129 (German Research Foundation, DFG; TP14 to S.B. and TP2 to D.G.). S.B. was supported by a research grant from the Chica and Heinz Schaller Foundation . V.S. and O.S. are grateful to the Beatrix-Lichtken-Stiftung Cologne for funding. Z.Y. and J.Q. appreciate funding through grant AI139572 from the National Institute of Allergy and Infectious Diseases, NIH , USA. This work was further supported by the gravitation program NOCI: 024.003.001 from the Netherlands Organisation for Scientific Research (NWO). Finally, we thank Janina Haar for sharing various primary cells including human hepatocytes and cells shown in Figure 4 A; Manuela Nickl for providing T cells; as well as Andrea Imle, Kathleen Börner, and David Bejarano (all Department of Infectious Diseases/Virology, Heidelberg University Hospital, Heidelberg, Germany) for preparing and providing PBMCs and macrophages.
Publisher Copyright:
© 2019 The Author(s)
PY - 2019/3/15
Y1 - 2019/3/15
N2 - Parvoviruses are highly attractive templates for the engineering of safe, efficient, and specific gene therapy vectors, as best exemplified by adeno-associated virus (AAV). Another candidate that currently garners increasing attention is human bocavirus 1 (HBoV1). Notably, HBoV1 capsids can cross-package recombinant (r)AAV2 genomes, yielding rAAV2/HBoV1 chimeras that specifically transduce polarized human airway epithelia (pHAEs). Here, we largely expanded the repertoire of rAAV/BoV chimeras, by assembling packaging plasmids encoding the capsid genes of four additional primate bocaviruses, HBoV2–4 and GBoV (Gorilla BoV). Capsid protein expression and efficient rAAV cross-packaging were validated by immunoblotting and qPCR, respectively. Interestingly, not only HBoV1 but also HBoV4 and GBoV transduced pHAEs as well as primary human lung organoids. Flow cytometry analysis of pHAEs revealed distinct cellular specificities between the BoV isolates, with HBoV1 targeting ciliated, club, and KRT5+ basal cells, whereas HBoV4 showed a preference for KRT5+ basal cells. Surprisingly, primary human hepatocytes, skeletal muscle cells, and T cells were also highly amenable to rAAV/BoV transduction. Finally, we adapted our pipeline for AAV capsid gene shuffling to all five BoV isolates. Collectively, our chimeric rAAV/BoV vectors and bocaviral capsid library represent valuable new resources to dissect BoV biology and to breed unique gene therapy vectors.
AB - Parvoviruses are highly attractive templates for the engineering of safe, efficient, and specific gene therapy vectors, as best exemplified by adeno-associated virus (AAV). Another candidate that currently garners increasing attention is human bocavirus 1 (HBoV1). Notably, HBoV1 capsids can cross-package recombinant (r)AAV2 genomes, yielding rAAV2/HBoV1 chimeras that specifically transduce polarized human airway epithelia (pHAEs). Here, we largely expanded the repertoire of rAAV/BoV chimeras, by assembling packaging plasmids encoding the capsid genes of four additional primate bocaviruses, HBoV2–4 and GBoV (Gorilla BoV). Capsid protein expression and efficient rAAV cross-packaging were validated by immunoblotting and qPCR, respectively. Interestingly, not only HBoV1 but also HBoV4 and GBoV transduced pHAEs as well as primary human lung organoids. Flow cytometry analysis of pHAEs revealed distinct cellular specificities between the BoV isolates, with HBoV1 targeting ciliated, club, and KRT5+ basal cells, whereas HBoV4 showed a preference for KRT5+ basal cells. Surprisingly, primary human hepatocytes, skeletal muscle cells, and T cells were also highly amenable to rAAV/BoV transduction. Finally, we adapted our pipeline for AAV capsid gene shuffling to all five BoV isolates. Collectively, our chimeric rAAV/BoV vectors and bocaviral capsid library represent valuable new resources to dissect BoV biology and to breed unique gene therapy vectors.
KW - AAV
KW - adeno-associated virus
KW - bocavirus
KW - BoV
KW - capsid engineering
UR - http://www.scopus.com/inward/record.url?scp=85060847600&partnerID=8YFLogxK
U2 - 10.1016/j.omtm.2019.01.003
DO - 10.1016/j.omtm.2019.01.003
M3 - Article
AN - SCOPUS:85060847600
VL - 12
SP - 202
EP - 222
JO - Molecular Therapy - Methods and Clinical Development
JF - Molecular Therapy - Methods and Clinical Development
ER -